Carotenoids modulate antioxidant pathways in In vitro models of Parkinson's disease: A comprehensive scoping review

Parkinson's disease (PD) is the second most common neurodegenerative disease, and it has affected the living quality of elderly people significantly. PD is characterised by the accumulation of α-Synuclein and progressive loss of dopaminergic neurons at the substantia nigra pars compacta. In the pathogenesis of Parkinson's disease, α-Synuclein, oxidative stress, and electron transport chain (ETC) are the three main factors that contribute to the production of reactive oxygen species (ROS). Currently, there is no commercial disease-modifying agent available for PD; the first-line treatment, Levodopa (l-DOPA), could only relieve the symptoms of PD, with many side effects. Carotenoids, which encompass red, orange, and yellow pigments found in nature and contribute to the colouration of plants, have been associated with various health benefits, including anti-cancer and neuroprotective effects due to their antioxidant properties. This scoping review delves into the impact and underlying mechanisms of carotenoids on cell-based models of neurodegenerative diseases.